From Chemical to Drug – The Path to a Small Molecule IND

San Francisco, CA

9/21/2017

12:30pm - 5:00pm

Do you have a solid plan to achieve IND acceptance? Filing an Investigational New Drug (IND) application might be the next step in advancing your company’s early-stage drug development program. Johnson & Johnson Innovation, JLABS (JLABS) and Janssen Discovery Sciences invite you to an in-depth look into the process of filing an IND. Whether your goal is to develop a pipeline through commercial launch or partner as early as possible, submitting an IND is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a clear blueprint for IND approval, and we want you to be ready.

The presentations will highlight the following:

-Janssen Research & Development – your partner of choice
-Preclinical Development Strategies for pharmacokinetics, drug metabolism and toxicology
-Role of patient behavior in development of solutions
-Key CMC strategies to balance cost, time and quality risks
-Designing First-in-Human trials to highlight the qualities of your molecule
-Regulatory strategy, IND requirements, and Pre-IND meetings

Click Here for More Information

Contact: Nikki Sarantinos
Contact Email: nsarant1@its.jnj.com

Event Address:

Byers Hall Auditorium
University California San Francisco
600 16th St.
San Francisco, CA